Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$4.39 USD
+0.35 (8.66%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $4.29 -0.10 (-2.28%) 6:26 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRCA 4.39 +0.35(8.66%)
Will VRCA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
Other News for VRCA
Verrica Pharmaceuticals (VRCA) Gains Approval for YCANTH in Japan
New 52 Week Closing Low appears for VRCA after 8.39% move
12 Health Care Stocks Moving In Friday's Pre-Market Session
Verrica Pharmaceuticals development partner receives approval for YCANTH
Verrica Pharmaceuticals development partner receives approval for YCANTH